iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction
← catalyst calendarSponsored by SI-BONE, Inc. (industry) · SIBN — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
110estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-23 | actual | When the study began enrolling |
| Primary completion | 2025-04-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sacroiliac Joint Dysfunction
- Sacroiliac; Fusion
- Sacroiliac Disorder
- Sacroiliac Joint Pain
Intervention
- Device: Use of iFuse TORQ
Primary outcome
what the primary-completion date above is the date OFChange in SI joint pain measured by numerical rating scale (NRS)
measured At baseline and 6 months
Publications
- PMID 40574607 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SIBN's whole pipeline · Catalyst calendar · Every registered study · What changed